Literature DB >> 16919783

CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment.

J Jensen1, A R Langkilde, J L Frederiksen, F Sellebjerg.   

Abstract

An increased percentage of blood CD8+ T cells from patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS) was found to express CD26 and CD69. The percentage of CD26 or CD69 positive CD8+ T cells was higher in patients with MRI evidence of disease dissemination in space or with active MRI lesions than in the remaining patients. Treatment of MS with interferon (IFN)-beta resulted in a decrease in the percentage of CD26 and CD71 positive CD8+ T cells and an increase in the percentage of CD8+ T cells that expressed interleukin (IL)-10 and IL-13. CD8+ T cell activation in MS may be linked to disease activity already at disease onset, and is regulated by treatment with IFN-beta.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919783     DOI: 10.1016/j.jneuroim.2006.06.024

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

Review 1.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

2.  Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Authors:  Finn Sellebjerg; Martin Krakauer; Signe Limborg; Dan Hesse; Henrik Lund; Annika Langkilde; Helle Bach Søndergaard; Per Soelberg Sørensen
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

3.  Exploring the Mechanism of Yiqi Qingre Ziyin Method in Regulating Neuropeptide Expression for the Treatment of Atrophic Rhinitis.

Authors:  Lixing Lu; Xueran Kang; Bin Yi; Chenyan Jiang; Xiaojun Yan; Bin Chen; Yuxing Sun; Fangze Shi; Yuanbo Luo; Yisheng Chen; Runjie Shi
Journal:  Dis Markers       Date:  2022-03-08       Impact factor: 3.434

4.  Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

Authors:  Lars Börnsen; Jeppe Romme Christensen; Rikke Ratzer; Annette Bang Oturai; Per Soelberg Sørensen; Helle Bach Søndergaard; Finn Sellebjerg
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.